Supplementation with cholecalciferol during pregnancy linked to increased bone mineral content, bone mineral density, lean mass in offspring ...
The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...
Source: Getty Images “The potential adverse impact of chemotherapy exposure during pregnancy is likely mediated through ...
Researchers analyzed whole-genome sequencing data from 76,805 patients to identify variants in 4 genes that are associated ...
The Food and Drug Administration (FDA) has expanded the approval of Nerivio ® (Theranica) to include the acute and/or ...
According to the Company, the product is expected to be available in the coming weeks through Biologics by McKesson and Limited Specialty Distribution. The Food and Drug Administration (FDA) has ...
One year after reports of supply chain issues, 49% of reports in the US and 34% of reports in Canada were associated with ...
The new PDUFA target date is April 18, 2025. The Food and Drug Administration (FDA) has accepted for review the resubmitted supplemental Biologics License Application (sBLA) for Dupixent ...
The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.
The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback